메뉴 건너뛰기




Volumn 65, Issue 6, 2001, Pages 685-689

Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi

Author keywords

[No Author keywords available]

Indexed keywords

PRIMAQUINE; SITAMAQUINE;

EID: 0035687445     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2001.65.685     Document Type: Article
Times cited : (112)

References (16)
  • 14
    • 0030940539 scopus 로고    scopus 로고
    • Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years
    • (1997) Clin Infect Dis , vol.24 , pp. 684-703
    • Berman, J.D.1
  • 15
    • 0032618649 scopus 로고    scopus 로고
    • Editorial response: U.S. FDA approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis
    • (1999) Clin Infect Dis , vol.28 , pp. 49-51
    • Berman, J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.